Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 25 April 2013 | By Louise Zornoza
Under a new plan announced by Brazil's regulatory agency, Anvisa, even if Brazil fails to obtain EU recognition for its active pharmaceutical ingredient (API) good manufacturing practice (GMP) standards by the mandatory date of 2 July 2013, regulators will still provide Brazilian companies with a document indicating GMP compliance so facilitate exports of their APIs.
The Falsified Medicines Directive (Directive 2011/62/EU) was adopted in May 2011 to safeguard public health in the EU by protecting the pharmaceutical supply chain from infiltration by falsified (or counterfeit) medicines and introduced new rules to more rigorously regulate the supply chain.
According to the Directive, written confirmation of GMP compliance for exports of API to the EU will be required as of 2 July 2013 from countries that are not listed as having equivalent GMPs. Anvisa submitted a formal request to the EU in October 2012 to be part of that list and the European Commission is still assessing that request.
Brazilian companies that have valid GMP certificates will need to submit a petition to Anvisa using "CERTIFICATE-7239," the regulator said.
Read all Breaking News from RegLink
Europa altera requisitos para importação de insumos farmacêuticos
Tags: South America, Export, brazil, API, EU